COGNITION THERAPEUTICS INC
CGTXNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$47.8M | −$54.0M | −$50.7M | −$43.6M | −$28.6M | −$17.4M |
| Net income | −$23.5M | −$34.0M | −$25.8M | −$21.4M | −$11.7M | −$7.8M |
| Total assets | $48.4M | $30.2M | $35.2M | $50.4M | $59.1M | $7.1M |
| Total liabilities | $14.1M | $11.5M | $10.7M | $10.2M | $7.9M | $19.9M |
| Equity | $34.3M | $18.8M | $24.5M | $40.2M | $51.3M | −$68.2M |
| EPS (diluted) | $-0.32 | $-0.86 | $-0.86 | $-0.91 | $-3.13 | $-23.76 |
| Shares out. | 62.0M | 39.0M | 29.3M | 22.6M | 22.2M | 538,793 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −68.5%
- Return on assets
- −48.5%
- Return on capital (ROCE)
- −138.7%
- Liabilities / assets
- 29.2%
- Debt / equity
- 0.41×
- Book value / share
- $0.55
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -12.85distress
- Accruals / assets
- 2.3%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Bios Memory Spv I, LpActivist (13D)Sep 23, 2025
- Pathstone Family Office, LlcPassive (13G)Feb 4, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Doyle John BrendanOfficer — Chief Financial Officer | May 1, 2026 | Tax withholding | 8,567 | $1.28 |
| Doyle John BrendanOfficer — Chief Financial Officer | Apr 16, 2026 | Buy | 10,000 | $1.13 |
| Ricciardi LisaOfficer — CEO & President | Apr 16, 2026 | Buy | 9,175 | $1.10 |
| Caggiano AnthonyOfficer — Chief Medical Officer | Apr 16, 2026 | Buy | 10,000 | $1.11 |
| Ricciardi LisaOfficer — CEO & President | Feb 15, 2026 | Tax withholding | 5,850 | $1.12 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 7.8M | 9.7 | -2.8% |
| Apr 30, 2026 | 8.0M | 6.4 | +9.1% |
| Apr 15, 2026 | 7.3M | 6.6 | +6.8% |
| Mar 31, 2026 | 6.9M | 3.7 | -2.1% |
| Mar 13, 2026 | 7.0M | 10.7 | -1.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 21, 2026
- Results of operationsMay 7, 2026
- Results of operations · Regulation FD disclosureMar 26, 2026
- Other material eventMar 2, 2026
- Other material eventJan 27, 2026
- Entered a material agreement · Terminated a material agreementDec 18, 2025
- Results of operationsNov 6, 2025
- Other material eventSep 15, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KFORM 8-KMay 21, 2026
- 10-QMay 8, 2026
- 8-KFORM 8-KMay 7, 2026
- 4OWNERSHIP DOCUMENTMay 4, 2026
- ARSApr 27, 2026
- DEFA14AApr 27, 2026
- DEF 14AApr 27, 2026
- 4OWNERSHIP DOCUMENTApr 20, 2026
- 4OWNERSHIP DOCUMENTApr 20, 2026
- 4OWNERSHIP DOCUMENTApr 20, 2026
- S-8FORM S-8Mar 26, 2026
- 10-KMar 26, 2026
- 8-KFORM 8-KMar 26, 2026
- 8-KFORM 8-KMar 2, 2026
- 4OWNERSHIP DOCUMENTFeb 18, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.